Innate immunity and interferon in SARS-CoV-2 infection outcome.
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
11 07 2023
11 07 2023
Historique:
received:
08
05
2023
revised:
20
06
2023
accepted:
20
06
2023
pmc-release:
11
07
2024
medline:
14
7
2023
pubmed:
13
7
2023
entrez:
12
7
2023
Statut:
ppublish
Résumé
Innate immunity and the actions of type I and III interferons (IFNs) are essential for protection from SARS-CoV-2 and COVID-19. Each is induced in response to infection and serves to restrict viral replication and spread while directing the polarization and modulation of the adaptive immune response. Owing to the distribution of their specific receptors, type I and III IFNs, respectively, impart systemic and local actions. Therapeutic IFN has been administered to combat COVID-19 but with differential outcomes when given early or late in infection. In this perspective, we sort out the role of innate immunity and complex actions of IFNs in the context of SARS-CoV-2 infection and COVID-19. We conclude that IFNs are a beneficial component of innate immunity that has mediated natural clearance of infection in over 700 million people. Therapeutic induction of innate immunity and use of IFN should be featured in strategies to treat acute SARS-CoV-2 infection in people at risk for severe COVID-19.
Identifiants
pubmed: 37437537
pii: S1074-7613(23)00275-3
doi: 10.1016/j.immuni.2023.06.018
pmc: PMC10361255
mid: NIHMS1913673
pii:
doi:
Substances chimiques
Interferons
9008-11-1
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1443-1450Subventions
Organisme : NIAID NIH HHS
ID : U01 AI151698
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
J Interferon Cytokine Res. 2011 Jan;31(1):49-57
pubmed: 21190483
Inflammation. 2021 Dec;44(6):2151-2169
pubmed: 34524614
Sci Immunol. 2022 Jun 14;:eabp8966
pubmed: 35857576
Immunity. 2019 Sep 17;51(3):415-417
pubmed: 31533051
PLoS Biol. 2022 Oct 13;20(10):e3001805
pubmed: 36228039
Science. 2015 Jan 16;347(6219):269-73
pubmed: 25431489
Sci Rep. 2023 Apr 6;13(1):5629
pubmed: 37024541
EMBO J. 2022 Nov 2;41(21):e110727
pubmed: 36124427
Nat Microbiol. 2020 Nov;5(11):1330-1339
pubmed: 32704094
J Virol. 2017 Mar 13;91(7):
pubmed: 28077655
PLoS Biol. 2021 Dec 28;19(12):e3001490
pubmed: 34962926
Cell. 2020 Nov 12;183(4):1070-1085.e12
pubmed: 33031744
Mamm Genome. 2018 Aug;29(7-8):593-602
pubmed: 29982912
Curr Opin Virol. 2015 Dec;15:19-26
pubmed: 26231767
Front Immunol. 2021 May 12;12:657363
pubmed: 34054820
Immunity. 2019 Sep 17;51(3):451-464.e6
pubmed: 31471108
Cell. 2021 Jan 7;184(1):106-119.e14
pubmed: 33333024
Cell Host Microbe. 2021 Feb 10;29(2):267-280.e5
pubmed: 33357464
Antiviral Res. 2010 Sep;87(3):345-52
pubmed: 20547186
Nat Commun. 2021 Dec 10;12(1):7193
pubmed: 34893599
Immunity. 2020 Aug 18;53(2):245-247
pubmed: 32814024
Nat Commun. 2022 Apr 25;13(1):2237
pubmed: 35469023
J Interferon Cytokine Res. 2011 Jan;31(1):41-7
pubmed: 21142819
J Exp Med. 2022 Nov 7;219(11):
pubmed: 36112363
Nat Commun. 2021 Feb 11;12(1):961
pubmed: 33574281
Nat Immunol. 2019 Dec;20(12):1610-1620
pubmed: 31740798
J Virol. 2021 Jan 29;95(8):
pubmed: 33514628
Science. 2020 Oct 9;370(6513):241-247
pubmed: 32855215
mBio. 2020 Oct 16;11(5):
pubmed: 33067384
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Annu Rev Immunol. 2018 Apr 26;36:667-694
pubmed: 29677479
Vaccines (Basel). 2023 Feb 10;11(2):
pubmed: 36851285
Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2200413119
pubmed: 35576468
J Biol Chem. 2017 Mar 17;292(11):4674-4685
pubmed: 28130445
Viruses. 2023 Feb 14;15(2):
pubmed: 36851745
Elife. 2021 Aug 03;10:
pubmed: 34342578
Sci Immunol. 2021 Aug 19;6(62):
pubmed: 34413140
Cutis. 1995 Sep;56(3):144
pubmed: 8565597
Science. 2020 Aug 7;369(6504):712-717
pubmed: 32527928
Nat Immunol. 2019 Aug;20(8):1035-1045
pubmed: 31235953
J Exp Med. 2021 Oct 4;218(10):
pubmed: 34357402
Nat Commun. 2022 May 4;13(1):2442
pubmed: 35508460
Hum Genomics. 2022 Nov 19;16(1):60
pubmed: 36403064
Cell. 2021 Jan 7;184(1):76-91.e13
pubmed: 33147444
Nature. 2021 Mar;591(7848):92-98
pubmed: 33307546
Annu Rev Immunol. 2023 Apr 26;41:277-300
pubmed: 36716750
Mol Med. 2021 Oct 18;27(1):129
pubmed: 34663207
Front Immunol. 2022 Aug 17;13:957107
pubmed: 36059541
Science. 2020 Aug 7;369(6504):706-712
pubmed: 32527925
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Nat Commun. 2018 Sep 6;9(1):3603
pubmed: 30190477
Cell. 2021 Jan 7;184(1):92-105.e16
pubmed: 33147445
Blood. 2021 Aug 26;138(8):722-737
pubmed: 34436524
J Clin Immunol. 2021 Nov;41(8):1733-1744
pubmed: 34570326
J Leukoc Biol. 2023 Feb 1;113(2):164-190
pubmed: 36822175
Nat Genet. 2022 Feb;54(2):125-127
pubmed: 35027740
Elife. 2021 Mar 02;10:
pubmed: 33650967
Front Immunol. 2023 Jan 26;14:1069894
pubmed: 36776844
Lancet Respir Med. 2021 May;9(5):498-510
pubmed: 33556319
J Med Virol. 2022 Aug;94(8):3605-3612
pubmed: 35355296
Curr Opin Struct Biol. 2022 Dec;77:102467
pubmed: 36306674
Nat Rev Microbiol. 2023 Mar;21(3):178-194
pubmed: 36631691
Genes Immun. 2008 Mar;9(2):168-75
pubmed: 18094709
PLoS One. 2023 Mar 29;18(3):e0272826
pubmed: 36989209
J Mol Biol. 2022 Mar 30;434(6):167277
pubmed: 34599939
Immunol Res. 2006;35(1-2):27-40
pubmed: 17003507
Front Immunol. 2023 Feb 22;14:1048592
pubmed: 36911685
Biomedicines. 2023 Jan 27;11(2):
pubmed: 36830907
Nat Rev Immunol. 2015 Apr;15(4):231-42
pubmed: 25790790
Trends Immunol. 2012 Apr;33(4):190-7
pubmed: 22321608
EMBO Rep. 2023 Apr 5;24(4):e56660
pubmed: 36880581
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32750141
N Engl J Med. 2023 Feb 9;388(6):518-528
pubmed: 36780676
Science. 2015 Jan 16;347(6219):266-9
pubmed: 25431490
Viruses. 2022 Nov 18;14(11):
pubmed: 36423162
J Virol. 2022 Jun 8;96(11):e0036422
pubmed: 35588276
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
mBio. 2021 Dec 21;12(6):e0275621
pubmed: 34724828
Expert Rev Anti Infect Ther. 2022 May;20(5):741-747
pubmed: 34747295
Science. 2021 Oct 29;374(6567):eabj3624
pubmed: 34581622
J Virol. 2020 Aug 31;94(18):
pubmed: 32641482
Cell Rep. 2022 May 10;39(6):110799
pubmed: 35523172
Cell Rep. 2021 Jan 12;34(2):108628
pubmed: 33440148
J Immunol. 2022 Jan 15;208(2):247-256
pubmed: 35017214
J Clin Virol. 2023 Apr;161:105420
pubmed: 36913789
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Nat Rev Immunol. 2020 Sep;20(9):537-551
pubmed: 32203325
Curr Top Microbiol Immunol. 2007;316:295-313
pubmed: 17969453